Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial
2018
This 19-week, double-blind, placebo-controlled, randomized phase 2 study evaluated the efficacy, safety, and tolerability of adjunctive cariprazine (0.1–0.3 and 1.0–2.0 mg/day) as an antidepressant treatment for adults with treatment-resistant major depressive disorder (MDD) (NCT00854100). The prima
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
43
References
15
Citations
NaN
KQI